Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rainer Storb

Showing results (211-220 of 315) with videos related to

Pageof 32
Sort By:
Transplantation and Cellular Therapy|April 8, 2021
Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease ProphylaxisMasumi Ueda Oshima, Barry E Storer, Huiying Qiu, et al.
British Journal of Haematology|November 20, 2002
Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantationJ Maciej Zaucha, Marco Mielcarek, Alessandra Takatu, et al.
Blood|February 7, 2012
Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrowMarco Mielcarek, Barry Storer, Paul J Martin, et al.
Blood|June 19, 2002
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone aloneSibel Koc, Wendy Leisenring, Mary E D Flowers, et al.
Haematologica|September 22, 2022
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationEduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, et al.
Haematologica|January 12, 2019
Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasmsFederico Monaco, Bart L Scott, Thomas R Chauncey, et al.
The Journal of Allergy and Clinical Immunology|July 21, 2010
Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndromeLauri M Burroughs, Troy R Torgerson, Rainer Storb, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 16, 2008
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donorsTerry Furlong, Hans-Peter Kiem, Frederick R Appelbaum, et al.
British Journal of Haematology|May 20, 2003
Recombinant human macrophage colony-stimulating factor-induced thrombocytopenia in dogsKraig Abrams, Murad Y Yunusov, Sherrill Slichter, et al.
Journal of Clinical Immunology|May 10, 2002
Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectivesMarco Mielcarek, Brenda M Sandmaier, David G Maloney, et al.
Pageof 32

Showing results (211-220 of 315) with videos related to

Sort By:
Pageof 32
Transplantation and Cellular Therapy|April 8, 2021
Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease ProphylaxisMasumi Ueda Oshima, Barry E Storer, Huiying Qiu, et al.
British Journal of Haematology|November 20, 2002
Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantationJ Maciej Zaucha, Marco Mielcarek, Alessandra Takatu, et al.
Blood|February 7, 2012
Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrowMarco Mielcarek, Barry Storer, Paul J Martin, et al.
Blood|June 19, 2002
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone aloneSibel Koc, Wendy Leisenring, Mary E D Flowers, et al.
Haematologica|September 22, 2022
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationEduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, et al.
Haematologica|January 12, 2019
Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasmsFederico Monaco, Bart L Scott, Thomas R Chauncey, et al.
The Journal of Allergy and Clinical Immunology|July 21, 2010
Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndromeLauri M Burroughs, Troy R Torgerson, Rainer Storb, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 16, 2008
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donorsTerry Furlong, Hans-Peter Kiem, Frederick R Appelbaum, et al.
British Journal of Haematology|May 20, 2003
Recombinant human macrophage colony-stimulating factor-induced thrombocytopenia in dogsKraig Abrams, Murad Y Yunusov, Sherrill Slichter, et al.
Journal of Clinical Immunology|May 10, 2002
Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectivesMarco Mielcarek, Brenda M Sandmaier, David G Maloney, et al.
Pageof 32